Market LIVE
Published markets; coverage varies by country
Product profile · United States

IBRANCE

 ·  Patent Litigation & Settlement History ↓

IngredientPALBOCICLIB
Application typeNDA
Application212436
Product003
Dosage formTABLET
RouteORAL
Strength125MG
Approval date2019-11-01
Marketing statusPrescription
Status event—
ApplicantPFIZER
Product source

Current GenericRadar decision

Year—
SelectionEXISTING_GENERIC
ReviewCOMPLETED
Anchor type—
Anchor date—
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2024-06-05
Status event—

Final ANDA candidate 215570/003 on 2024-06-05. Source-level RLD/TE screen; earliest Final and exact Product source reference require independent review.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
RE477392027-03-05DS/DP ————
———
RE477392027-09-05— ————
—2027-09-05—
107237302034-02-08DS/DP ————
———
107237302034-08-08— ————
—2034-08-08—
110652502036-08-19DP ————
———
110652502037-02-19— ————
—2037-02-19—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
M-14—2028-09-16————Source
PED—2029-03-16————Source
I-995—2029-06-24————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
215570 / 003FINAL_APPROVAL · FINAL_APPROVED2024-06-05—ZYDUS LIFESCIENCES GLOBAL FZENEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 1 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
215570 / 003ZYDUS LIFESCIENCES GLOBAL FZEFINAL_APPROVAL · FINAL_APPROVED2024-06-05 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.